Spinoff spotlight

GLAXOSMITHKLINE PLC ADRs $46 is a spinoff buy. The company (New York symbol GSK; Manufacturing sector; ADRs outstanding: 2.7 billion; Market cap: $124.2 billion; Dividend yield: 4.7%; Takeover Target Rating: Medium; www.gsk.com) is a U.K.-based global healthcare firm that develops and sells products in three main markets: pharmaceuticals (50%… Read More

Latest pharma spinoff should pay off

Johnson & Johnson recently announced that it would spin off its consumer drug business as a separate firm. This follows several other big pharmaceutical firms, including Pfizer, GlaxoSmithKline and Merck, that have completed similar spinoffs.
The breakup will let Johnson & Johnson focus on its more-profitable… Read More

Spinoff and activist will benefit Glaxo

Pharmaceutical giant GlaxoSmithKline has stayed in an narrow range of $33 to $48 in the past five years as it struggled with high costs and poor acquisitions.
The company now plans to re energize its growth by spinning off its consumer business as a separate company… Read More

The U.K. is looking beyond Brexit and COVID

Last year was a difficult one for the U.K. and its economy due the coronavirus pandemic. But the outlook for 2021 is much more positive.
The rebound will come from the easing of COVID-19 restrictions as the pandemic slows and from the government’s extensive stimulus spending… Read More

Pfizer remains our top drug stock

We now see several promising opportunities emerging in the pharmaceutical drug industry, and we will probably recommend more drug stocks in the next few years. For now, we feel Pfizer offers our readers the best combination of growth and income in a pharma stock. Since… Read More